Next generation sequencing market is anticipated to reach USD 21.4 billion by 2025

The global next generation sequencing market is anticipated to reach USD 21.4 billion by 2025, according to a new report by Grand View Research, Inc. Increasing coverage of NGS is expected to drive use of precision medicine in oncology from research based setting to clinical cancer setting. Commercial payers are also engaged in reviewing the existing and novel tests in order to establish appropriate medical necessity criteria for their clinical and medical policies.

Moreover, improved understanding of the genetic markers of virulence and resistance provided by next generation sequencing is expected to drive demand of the technology in infectious disease diagnosis.

 View summary of this report, click the link below: 
http://www.grandviewresearch.com/industry-analysis/next-generation-sequencing-market

Further Key Findings from the Report suggest:

• Oncology accounted for the dominant share owing to phase-resolved and unambiguous results obtained by using single assay systems, and analysis program.
• Targeted resequencing dominated the market owing to its associated benefits such as implementation of the technique such as lower turnaround time and more manageable data sets.
• Academic usage of NGS accounted for the largest share with respect to market revenue by end uses and is anticipated to maintain its dominance.
• Higher adoption of this technology and platforms in university projects is expected to support the estimated share.
• Asia Pacific is estimated to witness the fastest growth over the forecast period owing to expected routing of a considerable portion of whole genome sequencing requirements herein.
• Key players operating in the NGS market include Illumina Inc., Agilent Technologies, BGI, Pacific Biosciences, Qiagen, Roche, Thermo Fischer Scientific, and Oxford Nanopore Technologies Ltd.
• Endeavors adopted by participants are such as acquisition of Enzymatics by Qiagen acquired solutions in order to enhance the product portfolio with respect to reagents needed in preparatory steps.

To get full details at:

http://www.grandviewresearch.com/industry-analysis/next-generation-sequencing-market

Pharmacy automation devices industry is projected to grow at a CAGR of 7.3% from 2014 to 2020 and reach over USD 8.99 Billion

Pharmacy automation involves automation and mechanization of tasks that include distribution and handling medication processes carried out in heath care centers and specialty pharmacy centers. The global pharmacy automation devices industry is projected to grow at a CAGR of 7.3% from 2014 to 2020 and reach over USD 8.99 billion.

Automation systems such as packaging and labeling systems, medication dispensing system, storage and retrieval systems, table-top counters and compounding systems are employed in order improve the efficacy of regular jobs within pharmacies. The market is expected to grow owing to features including system integration that increases productivity and time to clinicians for patient care, thereby lowering medication errors.

Rising demand for pharmaceutical products, progressively growing technology and demand for precise robotic equipment & tools to perform operations at a faster rate are expected to be the key factors for market growth. Untapped growth opportunities in countries such as Brazil, China, and India coupled with escalating demand for automation in pharmacy and healthcare operations is expected to drive growth over the forecast period.

The market was dominated by automated medication dispensing systems in 2013. It accounted for a share of over 47.8% owing to growing demand for accurate medication dispensing systems. Automated dispensing systems have the ability to reduce significantly error rates and the ability to dispense hands-free. They provide storage, recording of medication, distribution to resident care and computer controlled dispensation.

 view summary of this report, click the link below: 
http://www.grandviewresearch.com/industry-analysis/pharmacy-automation-market

Automated compounding systems are anticipated to grow rapidly at a CAGR of 8.4% from 2014 to 2020 owing to an increasing demand for mixing of medication and substantial decrease in total time to complete a dose.

The existence of IT healthcare systems and high rate of penetration in healthcare and pharmaceutical units resulted in North America occupying the largest regional market in 2013. It accounted for about 54.8% of the market revenue. Increasing healthcare overheads and R&D relevant to pharmacy automation devices are few factors responsible for its market share.

Asia Pacific is likely to grow at a CAGR of over 9.0% during the forecast period and is the most lucrative regional markets majorly due to improving healthcare infrastructure in emerging economies of China and India. Easy access available to new entrants including multinational pharmaceutical companies and distributors in this region coupled with the introduction of healthcare reforms in these countries is expected to drive market growth.

Key industry players include AmerisourceBergen Corporation, CareFusion Corporation, Accu-Chart Healthcare, ForHealth Technologies, GSE Scale Systems, Fulcrum Inc,McKesson Corporation, Innovation PharmaAssist Robotics, Pearson Medical Technologies, Health Robotics SRL, Kirby Lester, MedDispence, Pyxis Pharmacy Automation Systems, Medacist, MTS Medication Technologies, OmnicellInc, Cerner Corporation, Rice Lake Weighing Systems, Baxter International Inc., Aesynt Inc., ScriptPro LLC, Parat Systems Pharmacy Automation, Yuyama Co. Ltd, Swisslog Holding Ltd,Talyst Inc. and ScriptPro LLC.

To get full details at:

http://www.grandviewresearch.com/static/img/research/pharmacy-automation-market.png

Portable CT scan and X-ray device market are expected to reach USD 8.41 billion by 2020

The global portable CT scan and X-ray device market are expected to reach USD 8.41 billion by 2020. Increasing demand for home healthcare, bedside imaging, and growing use of CT scan to assess the accuracy of medical implants, post interventional medical procedures and anatomical confirmation are key factors driving industry growth.

Rising prevalence of diseases such as cancer, cardiovascular, dental and orthopedic disorder will also augment the growth of the market. Also, an increase in the number of medical implants surgeries owing to unhealthy lifestyle as well as growing base of geriatric population is expected to bolster demand.

The portable X-ray device were dominated by mobile X-ray machines on account of rising demand for core diagnostic and bedside imaging. These device also eliminate the requirement for multiple radiology departments in a healthcare institution, thus promoting industry growth. The handheld X-Ray device market is poised to experience substantial growth over the forecast period owing to high maneuverability and the introduction of products such as NOMAD Pro.

Portable CT scan device market was dominated by the medium slice scanners due to high image resolution capabilities and high usage rates. Medium slice scanner accounted for over 58% of portable CT scan by technology in 2013. Digital radiography, owing to increasing demand for manufacturing filmless X-ray and PACS based radiology device, is identified as the fastest growing technology among the overall market.

View summary of this report, Click Here

North America is expected to dominate the market demand for these device over the forecast period owing to high expenditure on healthcare, reimbursement framework and sophisticated healthcare infrastructure. However, Asia Pacific is expected to witness the fastest growth, growing at a CAGR of more than 9% owing to improving healthcare infrastructure particularly in emerging economies such as China and India. In addition, the advent of technologically advanced and economical products catering to cost sensitive clientele in the region will fuel the growth of the market.

Supportive government regulations in Asia Pacific promoting manufacturing in the region is expected to drive demand for portable medical machines. Furthermore, low labor cost coupled with abundant tier I companies is projected to propel portable medical machines manufacturing in the region. As a result, product cost is likely to decrease over the forecast period owing to technological advancements which in turn is expected to drive demand, particularly in the emerging economies.

Philips Healthcare was the dominant player in the portable X-ray machines market with a market share of over 17% in 2013. Philips possessed an extensive product portfolio ranging from stationary X-ray systems to digital and portable X-ray systems. Some of the other key players in the industry are Hitachi Medical Systems and Varian Medical Systems, GE Healthcare, and Siemens Healthcare.

To get full details at:

http://www.grandviewresearch.com/industry-analysis/portable-x-ray-and-ct-scan-devices-industry

Therapeutic bed market size is expected to reach USD 4.1 billion by 2024 - Grand View Research, Inc.

The global therapeutic bed market is expected to reach USD 4.1 billion by 2024, according to a new report by Grand View Research, Inc. The growing geriatric population base coupled with the rising cases of obesity, chronic conditions, and viral infections are expected to boost market growth over the forecast period. 

As per the U.S. Bureau of Labor Statistics, the rank of home health aides and personal care aides is expected to increase to 13.0 million in 2020 (a 70.0% increase from 2010), thereby increasing the demand for home care. This growth is expected to increase the sale of household therapeutic beds and propel growth over the forecast period. Considering that the treatment costs at home are lower than other settings, many patients are now preferring home healthcare, thus, ultimately increasing the demand for therapeutic beds in these facilities. 

Another macro factor promoting the Therapeutic Bed Market is the increase in the volume of healthcare settings across the globe. With the help of this grant, 17 new hospitals and the expansion of 137 hospitals and primary health centers are anticipated, thereby increasing the sale of therapeutic beds. Similarly, in Qatar, the number of hospital beds is expected to rise from 4,980 in 2013 to 5,725 in 2018. These expansions are expected to create new avenues for market players to capitalize on. 

View summary of this report, Click Here

Further key findings from the study suggest:

• The household bed segment is identified as the fastest growing. The growing penetration of home healthcare services for preventive care, post-operative care, and for long-term chronic therapies are expected to drive the growth over the forecast period.
• Clinical beds have been further sub-segmented into regular, ICU, pediatric, birthing, bariatric, low air loss, and other beds. Bariatric beds are expected to gain the highest application in regions such as the U.S., Canada, the UK, and Germany due to the rising number of obese population.
• North America is expected to dominate the overall market throughout the forecast period, owing to the presence of well-developed primary, secondary, tertiary care hospitals, the presence of a well-developed reimbursement network, government funding, and high public and private expenditure in the hospitals sector
• Asia Pacific is anticipated to be the fastest growing region. The market is expected to grow at a CAGR of about 7.0% over the forecast period. The hospital to beds ratio is below the WHO standards in several Asia Pacific countries and the governments are investing significant resources to improve the healthcare infrastructure in this region.
• Key players of the industry include Invacare Corporation, Hill-Rom, Inc., Stryker Corporation, ArjoHuntleigh, Gendron, Inc., Hard Manufacturing Co., Bakare, Medline Industries, Sunrise Medical, and GF Health Products, Inc. Most of these companies have been in the business for over a decade and are bringing in expertise and technological advancement that are expected to help them sustain over the forecast period.
• In order to curb competition, major market players are working towards the acquisition of emerging entrants. For instance, in January 2015, Stryker Corporation acquired the assets of CHG hospital Beds, Inc., a privately held company to enhance the low height bed designs portfolio. 

To get full details at:

http://www.grandviewresearch.com/industry-analysis/therapeutic-beds-market

Multiple sclerosis therapeutics market size is expected to reach USD 24.8 billion by 2024

The global multiple sclerosis therapeutics market is expected to reach USD 24.8 billion by 2024 according to a new report by Grand View Research, Inc.

The presence of high unmet clinical needs in developing regions is one of the highest impact rendering drivers of the multiple sclerosis therapeutics market. Many organizations over the globe are actively involved in spreading awareness among people regarding progressive multiple sclerosis and the symptoms associated with it. Some notable examples include the National Multiple Sclerosis Society (NMSS) in the U.S., Multiple Sclerosis International Federation in Canada, European Multiple Sclerosis Platform (EMSP), and the Multiple Sclerosis Society (MSC).

Reimbursement programs are also anticipated to enhance the penetration of multiple sclerosis drugs. For instance, In June 2014, Biogen Idec Canada, announced that its TECFIDERA drug for the treatment of MS is available for reimbursement in British Colombia through B.C PharmaCare.

The introduction of novel therapeutics with minimal dosage requirement and cost-effectiveness is further expected to favor market growth. For, instance Lemtrada by Sanofi needs to be administered 3-5 times per year as compared to Copaxone, which requires daily administration.

View summary of this report, click the link below: 

http://www.grandviewresearch.com/industry-analysis/multiple-sclerosis-therapeutics-market

Further key findings from the study suggest:

• The dominant drug class segment in 2015 was immunomodulators. Avonex, Betaseron, Copaxone, and Rebif were the key drugs capturing over 75% of market share in 2015.The introduction of Tecifedra, an oral immunomodulatory drug in 2015 has been a major breakthrough in this segment.
• The declining revenue of Copaxone, Gilenya, Avonex, and Tysabri is forecasted by considering the factors such as limited usage rates of these drugs owing to the availability of highly potent FDA-approved oral drugs, Aubigio and Tecfidera
• Immunosuppressant,on the other hand, is expected to witness significant growth of over 18.0%. The presence of a strong drug pipeline and its expected commercialization in the coming six years are some factors expected to drive market growth
• In 2015, the injectable drugs market held the largest share owing to high prescription rates & price
• North America dominated the overall multiple sclerosis therapeutics market with revenue estimates at over 13.0 billion in 2015. The increasing prevalence of multiple sclerosis, the introduction of new drugs, and high prices of drugs, such as Tysabri and Aubagio in the U.S., are some factors responsible for its dominance.
• Major companies operating in this market are Biogen Idec, Teva Pharmaceuticals, Bayer Healthcare, Pfizer, Sanofi Aventis, Merck, Novartis, and AbbVie. Market players are upgrading the product portfolio by launching generic versions to sustain its market position. For instance, in 2015, Novartis launched a generic version of Copaxone named Glatopa in the U.S.

To get full details at:

http://www.grandviewresearch.com/industry-analysis/multiple-sclerosis-therapeutics-market

Molecular Diagnostics Market is expected to reach over USD 17.9 billion by 2024 - Grand View Research, Inc.

Global molecular diagnostics market is expected to reach over USD 17.9 billion by 2024, based on a new report by Grand View Research, Inc. Increasing prevalence of infectious diseases including human papillomavirus and influenza is expected to be the primary driving force for the growth of the molecular diagnostics market. In the underdeveloped regions of Africa and Nigeria, other infections, such as HIV and tuberculosis, are soaring at a high growth rate since the last few years. This is estimated to increase the demand for early and accurate diagnostic techniques to curb their growth rate.

Prenatal genetic testing, performed for the purpose of early detection of abnormalities that develop in the fetuses of carrier parents, is also expected to widen the client base for the molecular diagnostics market. Moreover, the high adoption of unhealthy lifestyles further resulting in a large patient count afflicted with chronic diseases, such as diabetes and cardiovascular disorders, is also projected to positively impact the growth.

View summary of this report, click the link below: 
http://www.grandviewresearch.com/industry-analysis/molecular-diagnostics-market

Further key findings from the study suggest:

• The overall market is dominated by reagents with revenue generation of over USD 2.3 billion in 2015 owing to their elevated usage rates. Reagents are key products used in academic and research institutes to perform various molecular biology protocols further contributing toward the dominance of this segment.
• Instruments, such as PCR and next generation sequencing platforms, are being widely preferred by central laboratories and diagnostic institutes due to the rapid nature of these tests in delivering quick & reliable results and the high volume of diagnostic procedures in this segment. Thus, this segment is expected to maintain a constant growth at a CAGR of around 9.0%.
• Central laboratories led the global molecular diagnostics market by test location with revenue generation of around USD 4.0 billion in 2015 owing to their established base in the remote and developing regions
• On the other hand, the point of care devices segment witnessed the fastest growth with a CAGR of over 14.0%. The associated advantages include the user-friendly nature of these tests and quick healthcare delivery, which are estimated to propel the molecular diagnostics market.
• Infectious diseases held the largest share of over USD 2.9 billion in 2015. Molecular testing tools provide clinicians with better alternatives to detect countless infectious bacteria, virus, and pathogens in short time while delivering highly accurate results. Initiatives led by organizations, such as the WHO, in conducting diagnostic programs in regions with high risk areas is estimated to be a high rendering driver.
• The oncology segment is expected to exhibit a CAGR of around 13.0% over the forecast period. Rising awareness levels among people as well as healthcare professionals for cancer diagnosis is a key attribute propelling the market growth.
• The PCR segment dominated the market with revenue generation of over USD 2.6 billion in 2015, attributable to the growing applications of multiplex PCR over the conventional PCR procedure and the introduction of easy-to-use PCR handling kits.
• North America was observed to be the largest regional segment in 2015 with a share of over 45.0%. Key factors contributing toward the large share are well-established healthcare infrastructure, rising healthcare spending, increasing awareness levels among patients, and expansion of R&D activities related to drug discovery and development.
• Asia Pacific is identified as a lucrative segment with a CAGR of approximately 17.0% over the forecast period. Rising demand for improved diagnostic technologies employed for the prevention of epidemics, unaddressed clinical needs, and recent activities by key players targeting expansion in this region are the major factors supporting the market growth.
• Some of the major players include Novartis AG (Grifols), Siemens Healthcare GmbH, Bio-Rad Laboratories, Inc., Alere, Inc., Danaher Corporation, bioMérieux SA, Sysmex Corporation, Becton, Dickinson and Company, Johnson & Johnson Services, Inc., Bio-Rad Laboratories, Inc., Bayer AG, Qiagen, Hologic, Inc. (Gen Probe), Cepheid, F. Hoffmann-La Roche Ltd, and Dako
• The key players are advancing strategic collaborations with major technology-based companies & diagnostic centers and expanding into the developing regions in an attempt to increase their market share and attain stability

To get full details at:

http://www.grandviewresearch.com/industry-analysis/molecular-diagnostics-market

DNA Testing Market is anticipated to reach USD 10.04 billion by 2022 - Grand View Research Inc.

Global DNA testing market is anticipated to reach USD 10.04 billion by 2022, according to a new study by Grand View Research Inc. Rise in developments in the field of genome sequencing and personalized DNA level diagnostic applications, a considerable growth in the number of patented research initiatives by the government and government funded projects are factors expected to drive demand during the forecast period.

Introduction of novel technologies for genome profiling are expected to boost progress of this industry over the forecast period. Furthermore, increasing incidences of chronic oncology and infectious diseases that depend on DNA prototyping for treatment and diagnosis using personalized medicine are anticipated to significantly raise demand for DNA diagnostics/testing based research thereby propelling industrial growth in the coming years. Increasing demand for prenatal testing and in-vitro fertilization that subsequently leads to rise in demand for DNA diagnostics/testing is also attributive towards expected progress in this market.

View summary of this report, click the link below: 

http://www.grandviewresearch.com/industry-analysis/dna-testing-market

Further key findings from the study suggest:

• PCR based diagnosis accounted for the largest share of the market revenue in 2014 as a result of higher preference rate coupled with higher availability of products and reagent kits of this segment.
• Next generation sequencing application for DNA testing is estimated to witness significant progress with a double digit CAGR of over 16% amongst the other technology segments due to presence of significant advantages offered by this technique of DNA identification and testing.
• Infectious disease diagnostics accounted for the largest market share in 2014 due to higher incidence rate of various infectious disorders which subsequently raises the demand for in-vitro nucleic acid based diagnostic tests for diagnosis and monitoring of disease progression.
• There are diverse applications of DNA testing market out of which oncology diagnostics and histopathology is estimated to register lucrative growth over the forecast period. Factors attributing for considerable growth potential in this segment include identification of cancer causing genes & associated research, and facilitation in mutation detection
• North America dominated the market in 2014, with revenue estimated at over USD 2,600 million. Presence of sophisticated healthcare infrastructure, rising incidence of genetic abnormalities, favorable government initiatives with respect to genetic diagnosis and its application in in-vitro fertilization are major factors driving growth of this region.
• Asia Pacific is anticipated to witness lucrative growth as a result of developments in health care infrastructure in this region coupled with presence of significant number of target population that is suffering with chronic as well as acute disorders. Government initiatives taken up herein are also attributive to influence sector growth to a great extent.
• Key participants of DNA testing industry include Abbott Laboratories, Agilent Technologies Inc., Illumina Inc., Beckman Coulter Inc., Bio-Rad Laboratories, Thermo Fisher Scientific, Applied Biosystems Group, Cepheid Inc., Transgenomic Inc., Siemens Healthcare, Roche Diagnostics, Qiagen, Illumina, GE Healthcare, Alere Inc, Affymetrix Inc., Hologic, Dako, and 454 Life Sciences.

To get full details at:

http://www.grandviewresearch.com/industry-analysis/dna-testing-market

Neurology devices market worth is expected to reach USD 10.8 billion by 2022 - Grand View Research, Inc.

Global neurology devices market is expected to reach USD 10.8 billion by 2022, according to a new report by Grand View Research, Inc. This expected growth in demand can be ascribed to growing need for development of different neurostimulation techniques with efficient and accurate algorithms for treatment of several CNS associated disorders.

Rise in incidence of cerebral stroke and other severe disorders such as Alzheimer’s disease, epilepsy, and Parkinsonism is expected to fuel demand of neurology devices thereby driving industry growth. According to National Institute of Neurological Disorders and Stroke (NINDS), approximately 50 million Americans are affected due to these disorders leading to high economic & disease costs burden for medical expenses coupled with loss of productivity. The industry is expected to witness a considerable increase in demand for CNS related therapeutic procedures over the forecast period.

View summary of this report, click here 

Further key findings from the study suggest:

• Neurostimulation devices accounted for over 50% of the revenue generated in the market for 2014. This large share can be attributed to the growing number of chronic CNS disorders, a globally ageing population and development of minimally invasive neurological and faster acting stimulation devices that attract higher market usage and penetration in the neurology devices market.
• Neurosurgery segment including ultrasonic aspirators, stereotactic systems, neuroendoscopes, and aneurysm clips are expected to witness considerable growth over the forecast period due to their essential nature of use in tumor removal and brain cell damage repair surgeries.
• North America dominated the market in 2014, with revenue estimated at over USD 2,400 million. Presence of sophisticated healthcare infrastructure, favorable government initiatives pertaining to pharmaceutical R&D, cancer research, neurological R&D investment, and the presence of a considerably large CNS disorder patient base are some drivers of this market.
• Asia Pacific is expected to witness lucrative CAGR of over 8.0% from 2015 to 2022 due to the presence of high-unmet medical needs coupled with rapidly rising healthcare R&D investment, and growing medical expenditures in emerging economies such as India and China. Supportive government initiatives pertaining to increasing investments by manufacturers and governments in neuro-informatics and high untapped market opportunities are the important factors accounting for the expected growth of market in this region over the forecast period.
• Key participants of the neurology devices market include Johnson and Johnson, B.Braun Melsungen AG, Boston Scientific Corporation, St. Jude Medical Inc Covidien PLC, Medtronic Inc., Johnson & Johnson, Magstim Co Ltd., W.L. Gore & Associates Inc., Integra Life Sciences Holdings Corp., Stryker Corp.
• Market participants are involved in R&D for development of advanced stimulation and neuromodulation techniques with minimally invasive procedures that are more preferable to the patients. Furthermore, collaborations with university as well as non-university based institutes that are engaged in neuroscience research are expected to boost sector growth in the coming years. 

To get full details at:

http://www.grandviewresearch.com/industry-analysis/neurology-devices-market

Super resolution microscopes market size is expected to reach USD 4.8 billion by 2022

super resolution microscopes market is expected to reach USD 4.8 billion by 2022, according to a new study by Grand View Research Inc. Increasing corporate funding and government support for microscopy, growing demand for nanotechnology and technological advancements are expected to serve this market as high impact rendering drivers. Fluorescence imaging using conventional microscopy has encountered various advances in approximately all the limiting factors from speed to sensitivity. Super resolution microscopes have enabled researchers to visualize uniquely the desired molecular species in three dimensions, cellular environment and also in the live cells.

Life science dominated the application segment of the super resolution microscopes market in terms of share in 2014. Super resolution microscopes are considered to be viable external substitutes of electron microscopes as they enable researchers to accurately image biological specimens. Increasing research and development pertaining to the fields of neurology and cell biology is expected to further fuel the growth of this market. Nanotechnology is expected to gain significant market share in the recent years due to the increasing requirement of industrial microscopes with the growing usage of smart phones and electronic components around the globe.

View summary of this report, click the link below: 
http://www.grandviewresearch.com/industry-analysis/super-resolution-microscopes-industry

Further key findings from the study suggest:

• STED microscopes are identified as the most lucrative sub-segment of the market. The fact that STED microscopes use de-convolution techniques rather than mathematics based principles for image capturing is the most important driver of this market.
• The PALM and STORM product segments accounted for a significant market share in 2014. Live three-dimensional imaging with 3 to 6 color imaging patterns are expected to gain usage rate over the forecast period.
• North America was the most revenue generating region of the market. The market contributed more than 35.0% of the revenue in 2014. Increasing number of funding programs and growing research and development expenditure in the developed North American economies especially the U.S. is expected to drive regional market growth over the forecast period.
• Asia Pacific is expected to spearhead future market growth. Growing interest of photonics companies and venture capitalists in the field of electronics and life sciences, in order to achieve alternate financing is the most vital growth driver of this market.
• Key players of the super resolution microscopes market include Leica Microsystems, Olympus Corporation, Nikon Corporation, Carl Zeiss and Hitachi High Technologies Corporation.

To get full details at:

http://www.grandviewresearch.com/industry-analysis/super-resolution-microscopes-industry

In-vitro toxicology testing market is expected grow at an estimated CAGR of 10.5% from 2015 to 2022

The global in-vitro toxicology testing market is expected to reach USD 44.7 billion by 2022 growing at an estimated CAGR of 10.5% from 2015 to 2022, according to a new report by Grand View Research, Inc. This expected rise in demand can be ascribed to novel and promising technologies in analytical laboratories. 

Advancement in bioinformatics based research for development of efficient software algorithms in order to carry out efficient stimulation of in-silico animal models in determination of toxicological response is expected to influence sector growth through to 2022. 

Furthermore, rapid up gradation of databases that serve information for toxicity profiling and lethal dose determination of different compounds is anticipated to create significant potential for growth in this market during the forecast period. 

Rise in government imposed restrictions and guidelines on usage of animals for pre-clinical research and toxicology testing is also attributive towards estimated progress in this industry.

Additionally, increasing R&D in biotechnology sector for enhancement in cell based assays and cell culture techniques, is anticipated to impart significant growth potential in this sector. 

view summary of this report, click the link below: 
http://www.grandviewresearch.com/industry-analysis/in-vitro-toxicology-testing-market

Further key findings from the study suggest:

• Pharmaceutical and cosmetic industry together accounted for almost 65% of total revenue generated in this sector for 2014. This large share can be attributed to rapid novel product launches for treatment of different diseased conditions wherein toxicological testing is the pre-requisite step. 

• Cell culture technology contributed for over 42% of the revenue generated in the industry with respect to technology owing to critical role of cell culture in biotechnological development and cell based analysis 

• Omics technology is anticipated to register lucrative growth thereby driving demand due to advancement in sequencing methods and availability of different platforms depending on source and target sequence. 

• As a fundamental process in biopharmaceutical or pharmaceutical product development toxicological testing finds application in determination of systemic, dermal, & ocular toxicity as well as endocrine disruption 

• Amongst the above enlisted applications, dermal toxicity is expected to witness significant progress with a CAGR of approximately 13% due to comparatively higher incidence of side effects associated with skin after administration of several compounds. 

• North America accounted for the largest share of over 45% in revenue in 2014 owing to presence of significant number of sector players that are implementing advanced in-vitro technology. Furthermore, presence of stringent regulations pertaining to animal usage in toxicity analysis attributive towards high demand of in-vitro tests in this region. 

• Asia Pacific is expected to witness lucrative CAGR of over 11% from 2015 to 2022 due to rapid improvement in health care infrastructure in developing economies of this region which in turn contributes to regional progress in industry. 

• Key participants of in-vitro toxicology testing industry are Quest Diagnostics, Covance, Cyprotex, Alere, Inc, Charles River Laboratories, GE Healthcare, Thermo Fisher Scientific, Eurofins Scientific, Inc., Agilent Technologies, Catalent Pharma Solutions, Sigma Aldrich, and Bio-Rad. 

• These participants are involved in collaborations with bioinformatics research firms in order to develop novel in-silico algorithms for computational estimation of toxicity of pharmaceutical and chemical products. 

• Moreover, these market entities are also focusing on entering untapped regions in order to maintain their share in market revenue. 

To get full details at:

http://www.grandviewresearch.com/industry-analysis/in-vitro-toxicology-testing-market

Hemodynamic monitoring devices market size is expected to reach USD 1.4 billion by 2024 - Grand View Research, Inc.

The global hemodynamic monitoring devices market is expected to reach USD 1.4 billion by 2024, according to a new report by Grand View Research, Inc. The increasing demand for non-invasive monitoring techniques coupled with the rising prevalence of chronic illness is expected to drive the market over the forecast period. 

The hemodynamic monitoring market is influenced by new technologies such as echocardiography, thoracic electrical bio-impedance and others that maybe used to non-invasively monitor parameters such as cardiac output, arterial pressure, blood oxygen level, and central venous pressure. 

Furthermore, the rising population of critically ill patients coupled with defective healthcare facilities with drawbacks, such as understaffing, is propelling market players to develop minimal invasive hemodynamic monitoring devices that may be used in clinical and home care settings. Along with the new product development, the market is also anticipated to witness the development of technologies that help in the early diagnosis of shock and sepsis. 

Furthermore, efforts by key industry players to understand critical illnesses at molecular levels leading to the development of efficient assessment products are expected to be witnessed over the forecast period. Hence, all these company strategies and the research conducted are eventually expected to promote market growth over the forecast period.

view summary of this report, click the link below: 
http://www.grandviewresearch.com/industry-analysis/hemodynamic-monitoring-devices-market

Further key findings from the study suggest:

• The disposables segment is anticipated to be the largest segment by 2024. The rising sale of hemodynamic monitoring systems and increasing applications of these systems in home care settings, hospitals, and clinics are expected to boost the segment growth.
• The non-invasive devices segment is expected to be the fastest growing hemodynamic monitoring market. Risks that include the development of arrhythmias due to the use of pulmonary artery catheter and the development of other methodologies that measure the cardiac output, such as echocardiographs, are the vital impact rendering drivers.
• Asia Pacific is anticipated to be the fastest growing regions and is anticipated to contribute to about 20.0% of the global revenue by 2024. The strengthening of the distribution channels by companies and the registration of products in countries, such as China, India, Australia, and others, are expected to support the growth over the forecast period. For instance, LiDCO Group, in their 2016 prelim report emphasized on its strategy of appointing new distributors for the Australian and South East Asian region.
• Major industry players are Edward Lifesciences, LiDCO Group Plc, Deltex Medical, Philips Medical, GE Healthcare, Noninvasive Medical Technologies, Inc., Tensys Medical, Inc., Cardio-Dynamics International, and Drager Medical, Inc. As mentioned above, the new product development is expected to drive the market over the forecast period.
• For instance, in March 2016, the LiDCO Group received the U.S. FDA approval for the LiDCO unity and launched the product in the European region. Along the same time, LiDCO also succeeded in registering itself in China to explore untapped territories and increase their global presence.

To get full details at: 

http://www.grandviewresearch.com/industry-analysis/hemodynamic-monitoring-devices-market

Reprocessed medical devices market size is expected to reach USD 5.0 billion by 2022

The global reprocessed medical devices market is expected to reach USD 5.0 billion by 2022, according to a new study by Grand View Research, Inc. The increasing generation of medical waste coupled with the lack of centralized support for waste disposal in the healthcare industry is expected to drive the demand for reprocessed medical devices market. Additionally, the long-term cost-efficiency associated with these devices as compared to that of the original device is the high impact rendering driver of the industry. 

According to the Association of Medical Device Reprocessors (AMDR),hospitals witness up to 50% cost saving on every purchase of the reprocessed medical device, thereby spending only a limited amount, on waste disposal. 

Consequentially, reprocessing has also facilitated reduction in device cost by the original equipment manufacturer in a vain to compete with the third-party reprocessors, thus exerting a positive cumulative effect on the industry growth. 

Furthermore, the continuous deterioration of environmental conditions as a consequence of increasing landfills is anticipated to induce the demand for reprocessed medical devices. Reprocessing allows hospitals to divert over 8,000 pounds of Regulated Medical Waste (RMW) from landfills every year, thereby propelling the demand for the reprocessed medical devices market. 

The rising initiatives by organizations, such as Association of periOperative Registered Nurses, American Nursing Association, and Practice Greenhealth, in collaboration with governmental and intergovernmental agencies, pertinent to increasing awareness with respect to medical device reprocessing is further expected to provide lucrative growth platform to this industry in near future. 

View summary of this report, click the link below: 
http://www.grandviewresearch.com/industry-analysis/reprocessed-medical-devices-market

Further key findings from the study suggest:

• Cardiovascular devices dominated the product segment of the overall reprocessed medical devices market in terms of revenue share at over 55.0% in 2014,owing to a wide range of these devices approved by the U.S. FDA for diagnostics and therapeutics applications 

• Diagnostic electrophysiology catheters constituted the largest share at over 24.0% of the cardiovascular sub-segment in 2014 and positioning devices are expected to be the fastest growing at market over the forecast period. This can be attributed to the third-party processors involved in the reprocessing of single-use catheters due to high-cost savings 

• Hospitals held a substantial share of the end-use segment and constituted for over 40.0% of the overall market owing to increased in-house and third-party reprocessing due to the massive waste produced through resource users. The aforementioned provides lucrative opportunities for hospitals to contain the expenditure 

• As of 2014, North America dominated the overall reprocessed medical device market at over 47.0%owing to the presence of a large number of non-profit organizations, governmental, intergovernmental agencies, hospitals, donor agencies, and medical product manufacturers involved in reprocessing activities 

• Asia Pacific is anticipated to be the fastest growing regional market over the forecast period due to the presence of untapped opportunities in the emerging economies and rising investments in the healthcare infrastructure by global market players. This is predicted to impel growth in Asia Pacific 

• The key players in this industry are adopting collaborative strategies with public and private institutions and product approvals for business and geographical expansion. For instance, in January 2016,Centurion Medical Products Corporation acquired Nuvo-Med, Inc., a manufacturer of DisImpactor class I medical devices used for the treatment of fecal impaction in a probe to business expansion

To get full details at: 

http://www.grandviewresearch.com/industry-analysis/reprocessed-medical-devices-market